ClinicalTrials.gg
CompletedNCT05469100Updated Sep 18, 2025Results posted

A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function

A Phase 1 interventional study of Selpercatinib in Healthy and Renal Insufficiency, sponsored by Eli Lilly and Company. Completed at 6 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 3 years 7 months after the study started (first participant enrolled Dec 2018, registered Jul 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Renal Insufficiency by Eli Lilly and Company — 1 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Eli Lilly and Company.

Enrollment
3rd of 12
37 · median 30
Started
2018
with 2 others
Phase 1
12 of 12
1 open now
Registered
3rd of 12
by date

Among the 12 studies in Renal Insufficiency by Eli Lilly and Company, this one is the 3rd largest by enrollment, is one of 3 that started in 2018, is one of 12 in phase 1, and was the 3rd registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

1 of the 12 studies in Renal Insufficiency by Eli Lilly and Company is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Renal Insufficiency by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the amount of study drug that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to healthy participants. The study will last up to 9 days, excluding screening.

03

Conditions studied

  • Healthy
  • Renal Insufficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For all participants:

  • (BMI) ≥ 18.0 and ≤ 40.0 kilograms per meter squared (kg/m²) and had a minimum weight of at least 50 kg at screening
  • Have normal blood pressure, pulse rate, (ECG), and blood and urine laboratory test results that are acceptable for the study
  • Female of non : must have undergone sterilization procedures at least 6 months prior to the Screening
  • Males who are capable of fathering a child must agree to use from the time of the dose administration through 6 months after the last dose

For renal participants:

  • Participant has stable renal disease status and function at least 1 month prior to LOXO-292 administration.
  • Participant is not currently or has not previously being on hemodialysis
  • Baseline estimated (eGFR) based on the Modification of Diet in Renal Disease (MDRD) equation at screening as follows:

    • Severe Renal Impairment (RI): \< 30 milliliter per minute (mL/min)/1.73m²
    • Moderate RI: ≥ 30 and \< 60 mL/min/1.73m²
    • Mild RI: ≥ 60 and \< 90 mL/min/1.73m²

The MDRD equation is as follows (for females multiply result by 0.742, if African American multiply result by 1.212):

eGFR = 175 x [serum creatinine in milligrams per deciliter (mg/dL) measured with a standardized assay]\^-1.154 x (Age)\^-0.203

Exclusion criteria

Exclusion Criteria:

For renal participants:

  • Has rapidly fluctuating renal function, as determined by historical measurements; or has demonstrated or suspected renal artery stenosis. Rapidly fluctuating renal function is defined as or that differs by more than 20% within at least 3 months of the screening creatinine clearance or eGFR. If historical measurements are not available, then the 2 screening measurements will be used to demonstrate stability.
  • Participants who have had a renal transplant, a nephrectomy, or participants with a known history of nephrotic syndrome.
  • Participants who have required new medication for renal disease within 30 days prior to Check-in
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Selpercatinib (Control; Normal Renal Function)

    Participants with normal renal function (estimated glomerular filtration rate greater than or equal to \[eGFR ≥ 90 milliliters per minute (mL/min) per 1.73 square meters (m²)\] received a single 160 milligrams (mg) oral dose of Selpercatinib on Day 1, administered in a fasted state.

    Drug: Selpercatinib

  • Experimental
    Selpercatinib (Mild Renal Impairment)

    Participants with mild renal impairment (eGFR between 60 and 90 mL/min/1.73 m²) received a single 160 mg oral dose of Selpercatinib on Day 1, administered in a fasted state.

    Drug: Selpercatinib

  • Experimental
    Selpercatinib (Moderate Renal Impairment)

    Participants with moderate renal impairment (eGFR between 30 and 60 mL/min/1.73 m²) received a single 160 mg oral dose of Selpercatinib on Day 1, administered in a fasted state.

    Drug: Selpercatinib

  • Experimental
    Selpercatinib (Severe Renal Impairment)

    Participants with severe renal impairment (eGFR less than (\<) 30 mL/min/1.73 m² and not requiring hemodialysis) received a single 160 mg oral dose of Selpercatinib on Day 1, administered in a fasted state.

    Drug: Selpercatinib

Interventions

  • Administered orally

    Also known as: LY3527723, LOXO-292

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib in Plasma

    PK: AUC0-t of Selpercatinib

    Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose

  2. PK: Area Under the Concentration-time Curve, From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib in Plasma

    PK: AUC0-inf of Selpercatinib

    Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose

  3. PK: Percentage of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib.in Plasma

    PK: Percentage of AUC0-inf extrapolated was calculated as (1 - AUC0-t/AUC0-inf) \* 100.

    Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose

  4. PK: Maximum Observed Concentration (Cmax) of Selpercatinib in Plasma

    PK: Cmax of Selpercatinib

    Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose

  5. PK: Time to Maximum Observed Plasma Concentration (Tmax) of Selpercatinib in Plasma

    PK: Tmax of Selpercatinib

    Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose

  6. PK: Apparent First Order Terminal Elimination Rate Constant (Kel) of Selpercatinib in Plasma

    PK: Apparent terminal elimination rate constant; represents the fraction of drug eliminated per unit time calculated by linear least squares regression analysis using the maximum number of points in the terminal log linear phase (e.g., three or more non zero plasma concentrations).

    Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose

  7. PK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib in Plasma

    PK: t½ of Selpercatinib.

    Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose

  8. PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib in Plasma

    PK: CL/F of Selpercatinib

    Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose

  9. PK: Apparent Volume of Distribution During the Terminal Elimination Phase After Oral (Extravascular) Administration (Vz/F) of Selpercatinib in Plasma

    PK: Vz/F of Selpercatinib

    Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose

  10. PK: Unbound AUC0-t (AUC0-t,u) of Selpercatinib in Plasma

    AUC0-t,u was calculated by multiplying AUC0-t by Fu (i.e., AUC0-t\*Fu). Fu represented the unbound fraction of Selpercatinib in plasma, that is, the portion of the drug not bound to plasma proteins.

    Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose

  11. PK: Unbound AUC0-inf (AUC0-inf,u) of Selpercatinib in Plasma

    AUC0-inf,u was calculated by multiplying AUC0-inf by Fu (i.e., AUC0-inf\*Fu). Fu represented the unbound fraction of Selpercatinib in plasma, that is, the portion of the drug not bound to plasma proteins.

    Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose

  12. PK: Unbound Cmax (Cmax,u) of Selpercatinib in Plasma

    Cmax,u was calculated by multiplying Cmax by Fu (i.e., Cmax\*Fu). Fu represented the unbound fraction of Selpercatinib in plasma, that is, the portion of the drug not bound to plasma proteins.

    Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose

  13. PK: Unbound CL/F (CL/F,u) of Selpercatinib in Plasma

    CL/F,u was calculated by multiplying CL/F by Fu (i.e., CL/F\*Fu). Fu represented the unbound fraction of Selpercatinib in plasma, that is, the portion of the drug not bound to plasma proteins.

    Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose

  14. PK: Unbound Vz/F (Vz/F,u) of Selpercatinib in Plasma

    Vz/F,u was calculated by multiplying Vz/F by Fu (i.e., Vz/F\*Fu). Fu represented the unbound fraction of Selpercatinib in plasma, that is, the portion of the drug not bound to plasma proteins.

    Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose

  15. PK: Cumulative Amount of Selpercatinib Excreted (CumAe) in Urine

    PK: CumAe was reported. The urine sampling time points from pre-dose through 168 hours post-dose were used to assess this outcome.

    Time frame: Predose (spot collection), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours postdose

  16. PK: Cumulative Percentage of Administered Selpercatinib Dose (Cum%Dose) Excreted in Urine

    PK: Cum%Dose was reported. The urine sampling time points from pre-dose through 168 hours post-dose were used to assess this outcome.

    Time frame: Predose (spot collection), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours postdose

  17. PK: Renal Clearance (CLr) of Selpercatinib in Urine

    PK: CLr of Selpercatinib was reported.The urine sampling time points from pre-dose through 168 hours post-dose were used to assess this outcome.

    Time frame: Predose (spot collection), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours postdose

07

Results

Posted Sep 18, 2025

Participant flow

Participant flow — Overall Study
MilestoneSelpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)
Started13987
Received at least one dose of selpercatinib13987
Completed13987
Not completed0000

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib in Plasma

PK: AUC0-t of Selpercatinib

Time frame:
Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib in Plasma
nanogram*hour per milliliter (ng*hr/mL)Selpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib in Plasma19770 ± 52.123440 ± 36.029270 ± 25.620640 ± 71.0
PrimaryPK: Area Under the Concentration-time Curve, From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib in Plasma

PK: AUC0-inf of Selpercatinib

Time frame:
Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
PK: Area Under the Concentration-time Curve, From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib in Plasma
nanogram*hour per milliliter (ng*hr/mL)Selpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)
PK: Area Under the Concentration-time Curve, From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib in Plasma19870 ± 52.023510 ± 36.029470 ± 25.821000 ± 71.4
PrimaryPK: Percentage of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib.in Plasma

PK: Percentage of AUC0-inf extrapolated was calculated as (1 - AUC0-t/AUC0-inf) \* 100.

Time frame:
Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Mean · percentage of AUCextrap
PK: Percentage of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib.in Plasma
percentage of AUCextrapSelpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)
PK: Percentage of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib.in Plasma0.4856 ± 0.128190.2988 ± 0.107130.6738 ± 0.333981.706 ± 1.5917
PrimaryPK: Maximum Observed Concentration (Cmax) of Selpercatinib in Plasma

PK: Cmax of Selpercatinib

Time frame:
Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
PK: Maximum Observed Concentration (Cmax) of Selpercatinib in Plasma
nanogram per milliliter (ng/mL)Selpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)
PK: Maximum Observed Concentration (Cmax) of Selpercatinib in Plasma1399 ± 107.32247 ± 22.31742 ± 25.11006 ± 159.6
PrimaryPK: Time to Maximum Observed Plasma Concentration (Tmax) of Selpercatinib in Plasma

PK: Tmax of Selpercatinib

Time frame:
Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Median · hours (hr)
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Selpercatinib in Plasma
hours (hr)Selpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Selpercatinib in Plasma1.500 (1.00 to 24.00)1.500 (1.50 to 2.00)1.500 (1.00 to 3.00)1.000 (0.50 to 24.00)
PrimaryPK: Apparent First Order Terminal Elimination Rate Constant (Kel) of Selpercatinib in Plasma

PK: Apparent terminal elimination rate constant; represents the fraction of drug eliminated per unit time calculated by linear least squares regression analysis using the maximum number of points in the terminal log linear phase (e.g., three or more non zero plasma concentrations).

Time frame:
Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Mean · One per hour (1/hour)
PK: Apparent First Order Terminal Elimination Rate Constant (Kel) of Selpercatinib in Plasma
One per hour (1/hour)Selpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)
PK: Apparent First Order Terminal Elimination Rate Constant (Kel) of Selpercatinib in Plasma0.02853 ± 0.00434430.03434 ± 0.0124290.02662 ± 0.00478660.02204 ± 0.0061504
PrimaryPK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib in Plasma

PK: t½ of Selpercatinib.

Time frame:
Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Mean · hours (hr)
PK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib in Plasma
hours (hr)Selpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)
PK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib in Plasma24.854 ± 4.085022.632 ± 8.732827.139 ± 7.109133.828 ± 10.4879
PrimaryPK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib in Plasma

PK: CL/F of Selpercatinib

Time frame:
Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Mean · Liters per Hour (L/h)
PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib in Plasma
Liters per Hour (L/h)Selpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)
PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib in Plasma8.976 ± 4.65337.188 ± 2.61175.581 ± 1.38079.184 ± 6.5822
PrimaryPK: Apparent Volume of Distribution During the Terminal Elimination Phase After Oral (Extravascular) Administration (Vz/F) of Selpercatinib in Plasma

PK: Vz/F of Selpercatinib

Time frame:
Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Mean · Liter
PK: Apparent Volume of Distribution During the Terminal Elimination Phase After Oral (Extravascular) Administration (Vz/F) of Selpercatinib in Plasma
LiterSelpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)
PK: Apparent Volume of Distribution During the Terminal Elimination Phase After Oral (Extravascular) Administration (Vz/F) of Selpercatinib in Plasma334.5 ± 225.17227.9 ± 106.14219.4 ± 82.255444.7 ± 309.92
PrimaryPK: Unbound AUC0-t (AUC0-t,u) of Selpercatinib in Plasma

AUC0-t,u was calculated by multiplying AUC0-t by Fu (i.e., AUC0-t\*Fu). Fu represented the unbound fraction of Selpercatinib in plasma, that is, the portion of the drug not bound to plasma proteins.

Time frame:
Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
PK: Unbound AUC0-t (AUC0-t,u) of Selpercatinib in Plasma
nanogram*hour per milliliter (ng*hr/mL)Selpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)
PK: Unbound AUC0-t (AUC0-t,u) of Selpercatinib in Plasma533.1 ± 54.3659.7 ± 24.4856.3 ± 28.0709.9 ± 93.0
PrimaryPK: Unbound AUC0-inf (AUC0-inf,u) of Selpercatinib in Plasma

AUC0-inf,u was calculated by multiplying AUC0-inf by Fu (i.e., AUC0-inf\*Fu). Fu represented the unbound fraction of Selpercatinib in plasma, that is, the portion of the drug not bound to plasma proteins.

Time frame:
Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
PK: Unbound AUC0-inf (AUC0-inf,u) of Selpercatinib in Plasma
nanogram*hour per milliliter (ng*hr/mL)Selpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)
PK: Unbound AUC0-inf (AUC0-inf,u) of Selpercatinib in Plasma535.7 ± 54.3661.6 ± 24.4862.1 ± 28.1722.3 ± 93.9
PrimaryPK: Unbound Cmax (Cmax,u) of Selpercatinib in Plasma

Cmax,u was calculated by multiplying Cmax by Fu (i.e., Cmax\*Fu). Fu represented the unbound fraction of Selpercatinib in plasma, that is, the portion of the drug not bound to plasma proteins.

Time frame:
Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
PK: Unbound Cmax (Cmax,u) of Selpercatinib in Plasma
nanogram per milliliter (ng/mL)Selpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)
PK: Unbound Cmax (Cmax,u) of Selpercatinib in Plasma37.72 ± 113.663.23 ± 23.450.95 ± 28.534.60 ± 187.8
PrimaryPK: Unbound CL/F (CL/F,u) of Selpercatinib in Plasma

CL/F,u was calculated by multiplying CL/F by Fu (i.e., CL/F\*Fu). Fu represented the unbound fraction of Selpercatinib in plasma, that is, the portion of the drug not bound to plasma proteins.

Time frame:
Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Mean · Liters per Hour (L/h)
PK: Unbound CL/F (CL/F,u) of Selpercatinib in Plasma
Liters per Hour (L/h)Selpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)
PK: Unbound CL/F (CL/F,u) of Selpercatinib in Plasma337.9 ± 194.45247.9 ± 58.030191.6 ± 49.277300.6 ± 294.31
PrimaryPK: Unbound Vz/F (Vz/F,u) of Selpercatinib in Plasma

Vz/F,u was calculated by multiplying Vz/F by Fu (i.e., Vz/F\*Fu). Fu represented the unbound fraction of Selpercatinib in plasma, that is, the portion of the drug not bound to plasma proteins.

Time frame:
Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Mean · Liter (L)
PK: Unbound Vz/F (Vz/F,u) of Selpercatinib in Plasma
Liter (L)Selpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)
PK: Unbound Vz/F (Vz/F,u) of Selpercatinib in Plasma12700 ± 9498.58214 ± 4487.57697 ± 3676.114340 ± 12842
PrimaryPK: Cumulative Amount of Selpercatinib Excreted (CumAe) in Urine

PK: CumAe was reported. The urine sampling time points from pre-dose through 168 hours post-dose were used to assess this outcome.

Time frame:
Predose (spot collection), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours postdose
Reported as:
Mean · milligram (mg)
PK: Cumulative Amount of Selpercatinib Excreted (CumAe) in Urine
milligram (mg)Selpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)
PK: Cumulative Amount of Selpercatinib Excreted (CumAe) in Urine16.14 ± 9.529714.54 ± 3.161113.94 ± 5.32037.652 ± 5.4210
PrimaryPK: Cumulative Percentage of Administered Selpercatinib Dose (Cum%Dose) Excreted in Urine

PK: Cum%Dose was reported. The urine sampling time points from pre-dose through 168 hours post-dose were used to assess this outcome.

Time frame:
Predose (spot collection), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours postdose
Reported as:
Mean · percentage of dose excreted
PK: Cumulative Percentage of Administered Selpercatinib Dose (Cum%Dose) Excreted in Urine
percentage of dose excretedSelpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)
PK: Cumulative Percentage of Administered Selpercatinib Dose (Cum%Dose) Excreted in Urine10.09 ± 5.95609.087 ± 1.97578.713 ± 3.32524.782 ± 3.3881
PrimaryPK: Renal Clearance (CLr) of Selpercatinib in Urine

PK: CLr of Selpercatinib was reported.The urine sampling time points from pre-dose through 168 hours post-dose were used to assess this outcome.

Time frame:
Predose (spot collection), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours postdose
Reported as:
Mean · milliliter per hour (mL/hr)
PK: Renal Clearance (CLr) of Selpercatinib in Urine
milliliter per hour (mL/hr)Selpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)
PK: Renal Clearance (CLr) of Selpercatinib in Urine735.9 ± 230.39641.6 ± 243.96480.4 ± 208.23314.6 ± 94.084

Adverse events

Collected over Baseline up to 15 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Selpercatinib (Control; Normal Renal Function)0/13 (0%)0/13 (0%)2/13 (15.4%)
Selpercatinib (Mild Renal Impairment)0/9 (0%)0/9 (0%)3/9 (33.3%)
Selpercatinib (Moderate Renal Impairment)0/8 (0%)0/8 (0%)3/8 (37.5%)
Selpercatinib (Severe Renal Impairment)0/7 (0%)0/7 (0%)3/7 (42.9%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventSelpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)
HeadacheNervous system disorders1/130/92/80/7
NauseaGastrointestinal disorders0/132/90/80/7
SomnolenceNervous system disorders0/132/91/80/7
DiarrhoeaGastrointestinal disorders1/130/90/81/7
Muscle spasmsMusculoskeletal and connective tissue disorders0/130/90/81/7
DizzinessNervous system disorders0/130/90/81/7
DyspnoeaRespiratory, thoracic and mediastinal disorders0/130/90/81/7
Abdominal distensionGastrointestinal disorders0/131/90/80/7
ConstipationGastrointestinal disorders1/131/90/80/7
Dry mouthGastrointestinal disorders0/131/90/80/7

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Selpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)Total
Mean59.40 ± 6.4258.40 ± 6.2362.60 ± 6.0261.30 ± 5.8560.20 ± 6.14
Sex: Female, Male
Sex: Female, Male(Participants)Selpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)Total
Female632213
Male766524
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Selpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)Total
Hispanic or Latino431311
Not Hispanic or Latino967426
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Selpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)Total
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American734216
White664521
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Selpercatinib (Control; Normal Renal Function)Selpercatinib (Mild Renal Impairment)Selpercatinib (Moderate Renal Impairment)Selpercatinib (Severe Renal Impairment)Total
United States1398737
08

Study locations

6 sites
  • Anaheim Regional Center
    Anaheim, California 92801, United States
  • Stanford Health Care, Valley Care Program
    Pleasanton, California 94588, United States
  • Orange County Research Center
    Tustin, California 92780, United States
  • Riverside Clinical Research
    Edgewater, Florida 32132, United States
  • Clinical Pharmacology of Miami
    Miami, Florida 33014, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Aug 2019, 7 months.

Results were first posted in Sep 2025, 6 years 1 month after primary completion.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 7 months is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2022
First posted
Jul 21, 2022
StartActual
Dec 19, 2018
Primary completionActual
Aug 7, 2019
CompletionActual
Aug 7, 2019
Results first posted
Sep 18, 2025
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05469100
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Jul 21, 2022
Start date
Dec 19, 2018
Primary completion
Aug 7, 2019
Completion
Aug 7, 2019
Results posted
Sep 18, 2025
Last update
Sep 18, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selpercatinib

Start the discussion